Key multiple sclerosis companies such as Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, J-Pharma, Bristol-Myers Squibb, Polpharma Biologics, Repertoire Immune Medicines, Nervgen ...

DelveInsight’s multiple sclerosis competitive report depicts a robust space with 60+ active players working to develop 75+ pipeline multiple sclerosis treatments. Key multiple sclerosis companies such ...

Sanofi eyes filings for multiple sclerosis therapy tolebrutinib, although two of three phase 3 trials miss their primary endpoints.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. | ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Denali Therapeutics, Inc. DNLI announced that the FDA has accepted for review its biologics license application (BLA) for ...

Marisa Wexler is a senior science writer for Multiple Sclerosis News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of multiple ...